Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Impact of Age

Autologous hematopoietic cell transplantation (AHCT) has been shown to prolong survival in patients with multiple myeloma (MM), however adequate data is lacking in patients>70 years and less than 50 years of age. We retrospectively analyzed and compared the outcome of patients between the two age groups (>70 vs. ≤ 50 yrs.). Our study showed comparable outcomes between these two age groups.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research